There are few published data characterizing patterns of liver stiffness measurements (LSMs) among HCV-infected persons and their potential impact on clinical decisions (for example, deferring treatment and hepatocellular carcinoma surveillance).
Methods
A total of 591 HCV-infected injection drug users in a community-based cohort had four LSMs. We used semi-parametric latent class growth modelling to identify patterns, which then became a gold standard against which we characterized validity of information from the initial measurements.
Results
Median age was 49, 68% were male, 92% African-American and 33% HIV-coinfected. The median LSM at visit 1 was 6.7 kPa (IQR 5.3–8.8). Over a median 1.75 years, LSM measures were stable; median change between visits was 0 kPa (IQR -1.4–1.7). Only 3% had evidence of fibrosis progression. Other groups included stable patterns of no fibrosis (59%), moderate fibrosis (21%), severe fibrosis (7%) and cirrhosis (9%). Individuals with fibrosis progression were more likely to be HIV-infected than those with stable low fibrosis (P<0.001). The diagnostic accuracy of the first LSM for identification of need for cancer surveillance (cirrhosis ≥12.3 kPa) was high (positive predictive value =97%). Although no single low LSM had high negative predictive value for significant fibrosis (metavir <2), individuals with two or more low results rarely had progression.
Conclusions
These data underscore the stability of liver fibrosis in a cohort of predominantly African-American HCV-infected persons over 1.75 years, support using LSMs to monitor untreated persons at risk for progression and assess need for hepatocellular carcinoma surveillance.
References
1.
McHutchisonJ.G., MannsM.P., MuirA.J.Telaprevir for previously treated chronic HCV infection. N Engl J Med2010; 362: 1292–1303.
2.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet2010; 376: 705–716.
3.
BruixJ., ShermanM.Management of hepatocellular carcinoma. Hepatology2005; 42: 1208–1236.
4.
StraderD.B., WrightT., ThomasD.L., SeeffL.B.Diagnosis, management, and treatment of hepatitis C. Hepatology2004; 39: 1147–1171.
5.
LokA.S., McMahonB.J.Chronic hepatitis B: update of recommendations. Hepatology2004; 39: 857–861.
6.
Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B.September 14-16, 2002. Geneva, Switzerland. J Hepatol2003; 39Suppl 1: S1–S235.
7.
PoynardT., RatziuV., BedossaP.Appropriateness of liver biopsy. Can J Gastroenterol2000; 14: 543–548.
8.
BravoA.A., ShethS.G., ChopraS.Liver biopsy. N Engl J Med2001; 344: 495–500.
9.
Imbert-BismutF., RatziuV., PieroniL.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet2001; 357: 1069–1075.
10.
PatelK., GordonS.C., JacobsonI.Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol2004; 41: 935–942.
11.
SudA., HuiJ.M., FarrellG.C.Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology2004; 39: 1239–1247.
12.
FornsX., AmpurdanesS., LlovetJ.M.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology2002; 36: 986–992.
13.
WaiC.T., GreensonJ.K., FontanaR.J.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology2003; 38: 518–526.
14.
KelleherT.B., MehtaS.H., BhaskarR.Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol2005; 43: 78–84.
15.
LeroyV., MonierF., BottariS.Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol2004; 99: 271–279.
16.
FoucherJ., ChanteloupE., VergniolJ.Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut2006; 55: 403–408.
17.
Friedrich-RustM., OngM.F., MartensS.Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology2008; 134: 960–974.e8.
18.
StebbingJ., FaroukL., PanosG.A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol2010; 44: 214–219.
19.
TalwalkarJ.A., KurtzD.M., SchoenleberS.J., WestC.P., MontoriV.M.Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol2007; 5: 1214–1220.
20.
WilsonL.E., TorbensonM., AstemborskiJ.Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology2006; 43: 788–795.
21.
VlahovD., AnthonyJ.C., MunozA.The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr1991; 109: 75–100.
22.
SandrinL., FourquetB., HasquenophJ.M.Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol2003; 29: 1705–1713.
23.
CastéraL., VergniolJ., FoucherJ.Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology2005; 128: 343–350.
24.
KirkG.D., AstemborskiJ., MehtaS.H.Assessment of liver fibrosis by transient elastography in persons with HCV or HIV/HCV co-infection. Clin Infect Dis2009; 48: 963–972.
25.
CastéraL., FoucherJ., BernardP.H.Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology2010; 51: 828–835.
26.
NaginD.S.Group-based modeling of development. Cambridge, Massachusetts: Harvard University Press2005.
27.
JonesB.L., NaginD.S., RoederK.A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res2001; 29: 374–393.
28.
ArrandaleV., KoehoornM., McNabY., KennedyS.M.How to use SAS Proj Traj and SAS Proc Glimmix in respiratory epidemiology. Vancouver: School of Occupational & Environmental Hygiene, Department of Health Care & Epidemiology, University of British Columbia2006.
29.
MuthénB., MuthénL.K.Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res2000; 24: 882–891.
30.
Di BisceglieA.M., ShiffmanM.L., EversonG.T.Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med2008; 359: 2429–2441.
31.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
32.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
33.
GaneE.J., RobertsS.K., StedmanC.A.Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet2010; 376: 1467–1475.
34.
HarrisK.A., ArnstenJ.H., LitwinA.H.Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med2010; 4: 20–26.
35.
GrebelyJ., GenowayK., KharaM.Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy2007; 18: 437–443.
36.
ThomasD.L., AstemborskiJ., RaiR.M.The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA2000; 284: 450–456.
37.
MehtaS.H., LauB., AfdhalN.H., ThomasD.L.Exceeding the limits of liver histology markers. J Hepatol2009; 50: 36–41.
38.
VergniolJ., FoucherJ., TerrebonneE.Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology2011; 140: 1970–1979.e3.
39.
CastéraL., SebastianiG., LeB.B.Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol2010; 52: 191–198.
